All news

08/06/2015

PhD students, come and take part to the Bio Business Week !

BioBusiness Week 2015

After a successful first edition in 2014 … Save the Date ! The second edition will take place in Angers (France). Attend to a fast track training to create your start up, coached by professionals. Come with your scientific work, leave with a business plan.

28/04/2015

CESTI IHU and the creation of innovative companies

Through its scientific and medical goals, the CESTI IHU also aims to foster cooperation between academic research and companies, and, with its Atlanpole partner, to promote the emergence of start-up companies by using the results generated by the researchers involved in the program.

20/04/2015

MELSORT: a new therapeutic strategy for metastatic melanoma

MELSORT, sustained by the “IGO” LABEX research program aims at using adoptive transfer of melanoma specific T cells selected through an original technology for the treatment of metastatic melanoma. A phase I/II clinical trial based on this therapy has been validated by the French authorities and will begin in Nantes in June 2015 including 17 patients with metastatic melanoma.

15/04/2015

Effimune obtains regulatory approval for Phase I clinical trial in humans of its new immunomodulator FR104

Logo Effimune

[press release] Effimune announced that it had received the authorization from the Belgian regulatory authority, the FAMHP (Federal Agency for Medicines and Health Products) for a Phase I clinical trial of FR104, its drug candidate for controlling the regulation of the immune system. This double-blind randomized clinical trial will take place on 70 healthy volunteers (both men and women) over a period of 9 months, and will prepare the future development of FR104 in rheumatoid arthritis and kidney transplantation.

26/03/2015

Valneva Announces Approval of an EB66®-based Prototype Influenza Vaccine in Japan

Valneva

[Press release] Valneva announced today that the Chemo-Sero-Therapeutic Research Institute (Kaketsuken) has received manufacturing and marketing approval for a cell culture pandemic influenza vaccine (prototype) (General name: Emulsion Cell Culture Influenza HA Vaccine (Prototype)). This is a result of a co-development between GlaxoSmithKline and Kaketsuken.